PYC Therapeutics Ltd
ASX:PYC

Watchlist Manager
PYC Therapeutics Ltd Logo
PYC Therapeutics Ltd
ASX:PYC
Watchlist
Price: 1.7 AUD 8.97%
Market Cap: 991.5m AUD

Wall Street
Price Targets

PYC Price Targets Summary
PYC Therapeutics Ltd

Wall Street analysts forecast PYC stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PYC is 3.72 AUD with a low forecast of 2.32 AUD and a high forecast of 5.33 AUD.

Lowest
Price Target
2.32 AUD
37% Upside
Average
Price Target
3.72 AUD
119% Upside
Highest
Price Target
5.33 AUD
214% Upside
PYC Therapeutics Ltd Competitors:
Price Targets
FDMT
4D Molecular Therapeutics Inc
317% Upside
ALT
Altimmune Inc
373% Upside
KALV
Kalvista Pharmaceuticals Inc
100% Upside
SPRB
Spruce Biosciences Inc
154% Upside
SERA
Sera Prognostics Inc
42% Upside
XFOR
X4 Pharmaceuticals Inc
85% Upside
688331
RemeGen Co Ltd
16% Upside
6628
Transcenta Holding Limited
577% Upside

Revenue
Forecast

Revenue Estimate
PYC Therapeutics Ltd

For the last 13 years the compound annual growth rate for PYC Therapeutics Ltd's revenue is 22%. The projected CAGR for the next 3 years is 98%.

22%
Past Growth
98%
Estimated Growth
Estimates Accuracy
-47%
Average Miss

Operating Income
Forecast

Operating Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
PYC Therapeutics Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-51%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PYC's stock price target?
Price Target
3.72 AUD

According to Wall Street analysts, the average 1-year price target for PYC is 3.72 AUD with a low forecast of 2.32 AUD and a high forecast of 5.33 AUD.

What is PYC Therapeutics Ltd's Revenue forecast?
Projected CAGR
98%

For the last 13 years the compound annual growth rate for PYC Therapeutics Ltd's revenue is 22%. The projected CAGR for the next 3 years is 98%.

Back to Top